Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

Share :

2015 ASCO Annual Meeting

29 May - 2 Jun 2015
Published: 30 May 2015
Views: 2238
Rating:
Save
Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA

Dr Usmani presents at a press conference at ASCO 2015 a phase II trial that suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma.

Read the news article and watch the interview for more.

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )
28 Oct 2024

Advancements in paediatric Acute lymphoblastic leukemia management

Dr Ruchi Aujla - Balco Medical Center, Raipur, India
Advancements in paediatric Acute lymphoblastic leukemia management ( Dr Ruchi Aujla - Balco Medical Center, Raipur, India )
9 Oct 2024

Choosing 1st line TKI Wisely in patients with CML

Dr Prashant Mehta - Amrita Hospirtal, Karala, India
Choosing 1st line TKI Wisely in patients with CML ( Dr Prashant Mehta - Amrita Hospirtal, Karala, India )
26 Sep 2024

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg
ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )
15 Sep 2024

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda
Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )
6 Aug 2024

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda
Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )
6 Aug 2024

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )
27 Jun 2024

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )
25 Mar 2024

Relapsed refractory multiple myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India
Relapsed refractory multiple myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )
5 Dec 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation